ClinicalTrials.gg
Active, not recruitingNCT06543849ITTCUpdated Apr 11, 2025

The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients

An interventional study of Target Temperature Management Treatment in Targeted Temperature Management, Cardiac Arrest and Thrombin Function, sponsored by Tang Ziren. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Tang Ziren · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Heart Arrest with a site in China — 17 open to participants now, 22 under way, none of them phase 3. Heart Arrest · China.

Started
2024
with 3 others
No phase
5 of 37
2 open now
Primary completion
2025-12
later than 5 of 21 live
Registered
25th of 37
by date
Lead sponsor
5 of 37
Tang Ziren

Among the 37 studies in Heart Arrest with a site in China, this one is one of 4 that started in 2024, is one of 5 with no phase, reaches primary completion later than 5 of the 21 other live ones, and was the 25th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

17 of the 37 studies in Heart Arrest with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Heart Arrest with a site in China, or all of them as a file.
02

Study summary

This study will be a single-center, prospective, randomized controlled trial with an estimated sample size of 64 patients. Eligible patients will be randomly assigned in a 1:1 ratio to receive TTM for either 24 hours or 72 hours. The primary outcome measure will be the changes in thrombin function indices at various time points during TTM treatment in both groups. The secondary endpoints of the study include additional coagulation function indicators, the incidence of bleeding-related events between the two groups, the amount of blood products used, the incidence of thrombotic events, and the CPC scores at 28 days and 6 months for both groups.

03

Conditions studied

  • Targeted Temperature Management
  • Cardiac Arrest
  • Thrombin Function
  • Treatment Duration

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age between 18 and 80 years;
  2. Glasgow Coma Scale score of less than 8 upon admission;
  3. patients resuscitated after out-of-hospital cardiac arrest; and (4) patient or their legal representative has signed the form.

Exclusion criteria

Exclusion Criteria:

  1. cardiac arrest caused by irreversible factors such as trauma or poisoning;
  2. cardiac arrest due to terminal conditions like advanced cancer;
  3. uncorrected persistent cardiogenic shock, defined as a systolic blood pressure below 90 mmHg despite treatment with fluid resuscitation, vasopressors, and inotropic agents;
  4. pre-existing cerebrovascular disease or CT-confirmed intracerebral hemorrhage upon admission;
  5. pre-arrest Cerebral Performance Category (CPC) score between 3 and 5;
  6. bradycardia or sick sinus syndrome following the return of spontaneous circulation;
  7. pre-existing coagulation disorders or severe bleeding tendencies;
  8. pregnant or breastfeeding women, or women of childbearing age with elevated serum hCG levels;
  9. presence of treatment limitations (such as refusal by the patient or legal representative to undergo advanced life support, including mechanical ventilation, chest compressions, or targeted temperature management);
  10. determination by the principal investigator that the patient is unsuitable for the trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Sham comparator
    24-hour treatment

    Procedure: Target Temperature Management Treatment

  • Active comparator
    72-hour treatment

    Procedure: Target Temperature Management Treatment

Interventions

  • ProcedureTarget Temperature Management Treatment

    Target Temperature Management Treatment

06

What researchers measure

Primary outcomes

  1. Prothrombin Time (PT)

    The primary outcome measure is the statistical differences in prothrombin time (PT) between the two groups of patients at various time points.

    Time frame: 4 days

  2. Prothrombin Activity (PA)

    The primary outcome measure is the statistical differences in prothrombin activity (PA) between the two groups of patients at various time points.

    Time frame: 4 days

  3. Activated Partial Thromboplastin Time (APTT)

    The primary outcome measure is the statistical differences in activated partial thromboplastin time (APTT) between the two groups of patients at various time points.

    Time frame: 4 days

  4. Thrombin Time (TT)

    The primary outcome measure is the statistical differences in thrombin time (TT) between the two groups of patients at various time points.

    Time frame: 4 days

Secondary outcomes

  1. The concentration of D-dimer (D-D)

    The primary outcome measure is the statistical differences in D-dimer (D-D) between the two groups of patients at various time points.

    Time frame: 4 days

  2. International Normalized Ratio (INR)

    The primary outcome measure is the statistical differences in international normalized ratio (INR) between the two groups of patients at various time points.

    Time frame: 4 days

  3. The concentration of plasmin-α2-plasmin inhibitor complex (PIC)

    The primary outcome measure is the statistical differences in plasmin-α2-plasmin inhibitor complex (PIC) between the two groups of patients at various time points.

    Time frame: 4 days

  4. The concentration of fibrinogen (FBG)

    The primary outcome measure is the statistical differences in fibrinogen (FBG) between the two groups of patients at various time points.

    Time frame: 4 days

  5. The concentration of thrombin-antithrombin complex (TAT)

    The primary outcome measure is the statistical differences in thrombin-antithrombin complex (TAT) between the two groups of patients at various time points.

    Time frame: 4 days

  6. The concentration of thrombomodulin (TM)

    The primary outcome measure is the statistical differences in thrombomodulin (TM) between the two groups of patients at various time points.

    Time frame: 4 days

  7. The concentration of tissue-type plasminogen activator inhibitor complex (T-PAIC)

    The primary outcome measure is the statistical differences in tissue-type plasminogen activator inhibitor complex (T-PAIC) between the two groups of patients at various time points.

    Time frame: 4 days

  8. thrombelastogram (TEG)

    The primary outcome measure is the statistical differences in thrombelastogram (TEG) between the two groups of patients at various time points.

    Time frame: 4 days

  9. Platelet Count (PLT)

    The primary outcome measure is the statistical differences in platelet count (PLT) between the two groups of patients at various time points.

    Time frame: 4 days

  10. The rate of bleeding-related events

    The incidence of bleeding-related events in the two groups of patients, including gastric occult blood, fecal occult blood, intracerebral hemorrhage, or bleeding in other organs.

    Time frame: 4 days

  11. The Milliliters of blood products

    The usage of blood products, including red blood cells, platelets, and fresh frozen plasma.

    Time frame: 4 days

  12. CPC Score

    CPC = Cerebral Performance Category Score. The Secondary Outcome of the study is analyzed as the proportion of patients with good neurological outcome in the two groups, (CPC 1-2) at 6 months after CA.

    Time frame: 28 days and 6 months

Other outcomes

  1. The percentage of serious adverse events during the 4-day treatment period

    The primary safety measure is the percentage of serious adverse events during the 4-day treatment period, including any events that cause permanent damage to organs, are life-threatening, or result in death.

    Time frame: 4 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Starting 6 months after publication

Access criteria: The de-identified survey data will be made available for research purposes by contacting the corresponding authors

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.

Of 205 non-industry interventional studies with no phase under Heart Arrest, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 219 studies reached it within 28 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Aug 9, 2024
StartActual
Dec 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06543849
Lead sponsor
Tang Ziren
Responsible party
Tang Ziren (Professor, Capital Medical University) — Sponsor-investigator
First posted
Aug 9, 2024
Start date
Dec 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion